The Clinical Psychopharmacology Section conducts preclinical and clinical research into the mechanisms of action of cocaine. A major component of this project, conducted in collaboration with investigators at NIDDK is the synthesis and evaluation of potential treatment medications for cocaine addiction. The strong association of high risk behaviors related to the spread of HIV with cocaine addiction makes the effort to develop cocaine treatment medications highly related to the fight against AIDS. In this fiscal year we continued the effort to develop analogs of GBR12909 as putative cocaine antagonists or cocaine substitution- type medications. Previous studies in Rhesus monkeys showed that daily administration of GBR12909 and a long-acting ester derivative of GBR12909 1-[2-[Bis(4-fluorophenyl)methoxy[ethyl]-4- (3-hydroxy-3-phenylpropyl)piperaziny] decanoate suppresses cocaine self-administration without the development of tolerance. A single administration of this agent almost eliminated cocaine self-administration in Rhesus monkeys for one month. Other efforts demonstrated that the clinically available dopamine releaser, phentermine, decreased cocaine self-administration in Rhesus monkeys. A particularly important study demonstrated that administration of medications which increase both synaptic DA and 5-HT have no abuse liability yet decrease cocaine self- administration. Other efforts involve antagonists of the serotonin 4 receptor (5-HT4) as potential treatments of cocaine- induced cardiac arrhythmia. An important study demonstrated that a high affinity ligand for all three biogenic amine transporters blocks the ability of methamphetamine to release DA, 5-HT and NE. Clinical and laboratory experiments continued to demonstrate robust changes in the serotonergic systems during cocaine withdrawal. These results support the hypothesis that cocaine withdrawal is associated with a dual deficit of dopamine and serotonin and provide a strong rationale for the treatment of cocaine addiction with medications which affect both neurotransmitters.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000119-10
Application #
6535380
Study Section
(MDRB)
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2001
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Hampson, Robert E; Collins, Vernell; Deadwyler, Sam A (2009) A wireless recording system that utilizes Bluetooth technology to transmit neural activity in freely moving animals. J Neurosci Methods 182:195-204
Hampson, R E; EspaƱa, R A; Rogers, G A et al. (2009) Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717. Psychopharmacology (Berl) 202:355-69
Rothman, Richard B; Baumann, Michael H (2009) Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 8:317-29
Rothman, Richard B; Baumann, Michael H (2009) Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 16:354-64
Opris, I; Hampson, R E; Deadwyler, S A (2009) The encoding of cocaine vs. natural rewards in the striatum of nonhuman primates: categories with different activations. Neuroscience 163:40-54
Rothman, Richard B; Blough, Bruce E; Baumann, Michael H (2008) Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol 16:458-74
Pariser, Joseph J; Partilla, John S; Dersch, Christina M et al. (2008) Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. J Pharmacol Exp Ther 326:286-95
Gilbert, Kathleen M; Boos, Terrence L; Dersch, Christina M et al. (2007) DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. Bioorg Med Chem 15:1146-59
Rothman, Richard B; Blough, Bruce E; Baumann, Michael H (2007) Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 9:E1-10
Wang, X; Baumann, M H; Dersch, C M et al. (2007) Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan. Neuroscience 148:212-20

Showing the most recent 10 out of 59 publications